Recent blog posts
FDA Approves Biweekly TECVAYLI® for Refractory Multiple Myeloma
Latest Hotspot
3 min read
FDA Approves Biweekly TECVAYLI® for Refractory Multiple Myeloma
27 February 2024
FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.
Read →
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
Latest Hotspot
3 min read
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
27 February 2024
The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.
Read →
Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
Latest Hotspot
3 min read
Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
27 February 2024
Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.
Read →
Immune-Onc Therapeutics Announces Partnership for International Early-Stage Trial of IO-108 as First-Line Treatment for Advanced Liver Cancer
Latest Hotspot
3 min read
Immune-Onc Therapeutics Announces Partnership for International Early-Stage Trial of IO-108 as First-Line Treatment for Advanced Liver Cancer
27 February 2024
Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.
Read →
Monopar Begins Phase 1 Trial of MNPR-101-Zr Radiotherapy for Advanced Cancer
Latest Hotspot
3 min read
Monopar Begins Phase 1 Trial of MNPR-101-Zr Radiotherapy for Advanced Cancer
27 February 2024
Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.
Read →
FDA Approves Mabwell's IND Application for B7-H3-Targeted ADC, 7MW3711
Latest Hotspot
3 min read
FDA Approves Mabwell's IND Application for B7-H3-Targeted ADC, 7MW3711
27 February 2024
The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.
Read →
Initial Dosing of Tegavivint in Refractory Advanced Liver Cancer Study Begins
Latest Hotspot
3 min read
Initial Dosing of Tegavivint in Refractory Advanced Liver Cancer Study Begins
27 February 2024
Iterion Therapeutics stated that initial dosing has commenced in an early to mid-stage study of their drug Tegavivint for advanced liver cancer cases unresponsive to previous systemic therapies.
Read →
Teva Unveils Fresh Evidence for Anti-TL1A ('574) Antibody's Safe Use, Comfort and Efficacy at ECCO's 2024 Event
Latest Hotspot
4 min read
Teva Unveils Fresh Evidence for Anti-TL1A ('574) Antibody's Safe Use, Comfort and Efficacy at ECCO's 2024 Event
27 February 2024
Teva Pharmaceuticals has released encouraging initial results concerning the safety, patient tolerance, and pharmacokinetic profile of its investigational product known as anti-TL1A (TEV-’574).
Read →
NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
Latest Hotspot
3 min read
NextPoint Therapeutics Begins Clinical Trial for NPX887 Targeting HHLA2+ Solid Tumors
27 February 2024
NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.
Read →
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Latest Hotspot
3 min read
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
23 February 2024
argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.
Read →
Initial Human Trial of Arvinas's PROTAC® ARV-102 for Treating Neurological Conditions
Latest Hotspot
3 min read
Initial Human Trial of Arvinas's PROTAC® ARV-102 for Treating Neurological Conditions
23 February 2024
Arvinas Reports Initial Human Administration of Experimental PROTAC® Compound ARV-102 for Neurological Disorders Treatment.
Read →
Preliminary Phase III Outcomes of Onfekafusp Alfa for Advanced Soft Tissue Sarcoma
Latest Hotspot
3 min read
Preliminary Phase III Outcomes of Onfekafusp Alfa for Advanced Soft Tissue Sarcoma
23 February 2024
Philogen Announces Preliminary Results from Phase III FIBROSARC Study Evaluating Onfekafusp alfa (L19TNF) in Initial Treatment of Advanced or Metastatic Soft Tissue Sarcoma.
Read →